All Clinical Trials
View all active clinical trials around the US.
Verified
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics
OPTIMIZED CORD BLOOD TRANSPLANTSparkCures Verified Accurate, up-to-date information. Learn more
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENTAllogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
ALLO STEM CELL TRANSPLANT FOR GATA2 MUTATIONSTwo Step Haplo With Radiation Conditioning
RADIATION-BASED REDUCED INTENSITY CONDITIONINGMT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosp...
ALLOGENEIC STEM CELL TRANSPLANTHaplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood...
POST-TRANSPLANT CYCLOPHOSPHAMIDEAlpha/Beta TCD HCT in Patients With Inherited BMF Disorders
T CELL RECEPTOR DEPLETION IN STEM CELL TRANSPLANTABBA CORD: Double Umbilical Cord Blood Transplants With Abatacept for Graft Versus Host Disease Prophylaxis
ABATACEPT IN DOUBLE CORD BLOOD UNIT TRANSPLANTMyeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematologic...
MYELOABLATIVE ALLO STEM CELL TRANSPLANTA Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood ...
GRAFT VERSUS HOST DISEASE-REDUCTION STRATEGIESPersonalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelody...
PERSONALIZED NATURAL KILLER CELL THERAPYUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB TRANSPLANT WITH MYELOABLATIVE PREPDART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Rece...
DASATINIB & QUERCETIN WITH CAR-T CELL THERAPYPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hemato...
DONOR LYMPHOCYTE INFUSION POST TRANSPLANT²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEA Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide ...
CAR-T FOR PATIENTS WITH RENAL IMPAIRMENTFeasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
GVHD PREVENTION USING CLINIMACSUmbilical Cord Blood Transplantation From Unrelated Donors
UMBILICAL CORD BLOOD TRANSPLANTATIONA Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoi...
IS-FREE TREG STEM CELL TRANSPLANTPhase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymp...
CORD BLOOD-DERIVED NK CELLSMT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfa...
REDUCED INTENSITY CONDITIONING TREOSULFANPhase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
ELRANATAMAB + CYCLOPHOSPHAMIDEPeri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Synd...
RUXOLITINIB DURING STEM CELL TRANSPLANTRandomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Al...
RUXOLITINIB SWITCH-MAINTENANCE PROPHYLAXIS OF GVHDA Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of ...
CRISPR DELIVERED ANTI-BCMA CAR-TPilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILURE
Untreated / Newly Diagnosed Multiple Myeloma
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENT²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINE
Early Relapse Multiple Myeloma
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENTMyeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematologic...
MYELOABLATIVE ALLO STEM CELL TRANSPLANTPersonalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelody...
PERSONALIZED NATURAL KILLER CELL THERAPYUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB TRANSPLANT WITH MYELOABLATIVE PREPPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hemato...
DONOR LYMPHOCYTE INFUSION POST TRANSPLANT²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINE
Late Relapse Multiple Myeloma
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENTMyeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematologic...
MYELOABLATIVE ALLO STEM CELL TRANSPLANTPersonalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelody...
PERSONALIZED NATURAL KILLER CELL THERAPYUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB TRANSPLANT WITH MYELOABLATIVE PREPDART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Rece...
DASATINIB & QUERCETIN WITH CAR-T CELL THERAPYPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hemato...
DONOR LYMPHOCYTE INFUSION POST TRANSPLANT²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINE
Smoldering Myeloma
No active clinical trials
Monoclonal Gammopathy of Undetermined Significance (MGUS)
No active clinical trials